Outcomes of immunosuppression minimization and withdrawal early after liver transplantation
Authors:
Open Access
- 1 December 2018
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (5) , 1397-1409
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (UM1AI109565, UM2AI117870)
This publication has 22 references indexed in Scilit:
- Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized TrialAmerican Journal of Transplantation, 2017
- Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced TacrolimusTransplantation, 2015
- Is Minimal, [Almost] Steroid-Free Immunosuppression a Safe Approach in Adult Liver Transplantation? Long-term Outcome of a Prospective, Double Blind, Placebo-Controlled, Randomized, Investigator-Driven StudyAnnals of Surgery, 2014
- Immunosuppression minimization vs. complete drug withdrawal in liver transplantationJournal of Hepatology, 2013
- Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipientsHepatology, 2013
- Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled TrialAmerican Journal of Transplantation, 2012
- Complete Immunosuppression Withdrawal and Subsequent Allograft Function Among Pediatric Recipients of Parental Living Donor Liver TransplantsJAMA, 2012
- Evolution of Causes and Risk Factors for Mortality Post‐Liver Transplant: Results of the NIDDK Long‐Term Follow‐Up StudyAmerican Journal of Transplantation, 2010
- Tacrolimus Monotherapy in Liver TransplantationAnnals of Surgery, 2008
- Chronic Renal Failure after Transplantation of a Nonrenal OrganNew England Journal of Medicine, 2003